Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

CONCLUSIONS: Thus, ctDNA-based MRD monitoring appears to be a promising option to complement the overall assessment of pediatric AML patients, wherein patients with continuous ctDNA negativity have the option for treatment de-escalation in subsequent therapy. Importantly, patients with >3 log reduction but without clearance in ctDNA may not necessitate an aggressive treatment plan due to improved survival, but this needs further study to delineate.PMID:38170574 | DOI:10.1158/1078-0432.CCR-23-2589

Source: Clinical Cancer Research - January 3, 2024 Category: Cancer & Oncology Authors: Lipeng Liu Suyu Zong Aoli Zhang Yuanyuan Ren Benquan Qi Lixian Chang Wenyu Yang Xiaojuan Chen Yumei Chen Li Zhang Yao Zou Ye Guo Yingchi Zhang Min Ruan Xiaofan Zhu Source Type: research